Fosun Pharmaceuticals (02196): Empagliflozin metformin extended-release tablets (III) received registration approval

Zhitongcaijing · 1d ago

Zhitong Finance App News, Fosun Pharmaceuticals (02196) issued an announcement. Recently, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), the drug registration application for englicin metformin sustained-release tablets (III) (hereinafter referred to as the “drug”) was approved by the State Drug Administration. The approved indications are in combination with diet control and exercise, for adult patients with type 2 diabetes who are being treated with empagliflozin and metformin hydrochloride to improve blood sugar control in these patients.

This drug is a chemical developed independently by the Group (that is, the Company and its holding subsidiaries/units, the same below). As of June 2026, the Group's cumulative R&D investment for this drug at this stage is approximately RMB 17.92 million (unaudited).

According to the latest IQVIA CHPA data, in 2025, sales of metformin englicin tablets in China (excluding Hong Kong, Macao and Taiwan) were approximately RMB 674 million.